This study focuses on hereditary transthyretin amyloidosis (ATTRv) with the Val50Met variant in a non endemic aerea
We aim to describe the phenotypic variables including preclinical, cardiological, neurological, and mixed manifestations in patients carrying the Val50Met variant. Our goal is to identify early disease onset criteria in initially asymptomatic patients, enhancing early detection and treatment strategies. Participants will undergo various clinical examinations and tests to gather comprehensive data.
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
These interventions will be carried out in a time-controlled population within a family cluster of VAL50MET
Laboratory assessments include blood and urine sample collection for serum chemistry, hematology, and urinalysis, with specific biomarker analyses (troponin T, NT-proBNP, Kappa, and Lambda light chains
Charata, Chaco Province, Argentina